论文部分内容阅读
目的:观察对晚期胃癌患者应用伊立替康(CPT-11)与亚叶酸钙(CF)、氟尿嘧啶(5-Fu)联合化疗的近期疗效及毒副反应。方法:选择60例晚期胃癌患者,随机分为观察组和对照组,观察组30例,采用CPT-1180mg/(m2·w)ivgtt90minqw、CF500mg/(m2·w)IVgtt2hqw、5-Fu2000mg/(m2·w)CIV22hqw;对照组30例患者,采用奥沙利铂(L-OHP)130mg/m2IVgtt2hDay1、CF100mgIVgtt2h、5-Fu800mg/(m2·d)CIV22hDays1～521d为一周期。结果:观察组PR:13例;SD:10例;PD:7例,有效率为76.7%;对照组PR:11例;SD:10例;PD:9例,有效率为70.0%;两组比较(χ2=0.431,P>0.05)差异无统计学意义。结论:应用伊立替康与亚叶酸钙、氟尿嘧啶联合治疗胃癌晚期患者,临床效果非常明显,可作为晚期胃癌的一线化疗方案。
Objective: To observe the short-term curative effect and toxicity of combined use of irinotecan (CPT-11) and leucovorin (CF) and fluorouracil (5-Fu) in patients with advanced gastric cancer. Methods: Sixty patients with advanced gastric cancer were randomly divided into observation group and control group. The observation group consisted of 30 patients with CPT-1180mg / (m2 · w) ivgtt90minqw, CF500mg / (m2 · w) IVgtt2hqw, 5-Fu2000mg / · W) CIV22hqw; control group of 30 patients with oxaliplatin (L-OHP) 130mg / m2IVgtt2hDay1, CF100mgIVgtt2h, 5-Fu800mg / (m2 · d) CIV22hDays1 ~ 521d for a cycle. Results: In the observation group, there were 13 cases in the PR group, 10 cases in the SD group, 7 cases in the PD group, the effective rate was 76.7%, 11 cases in the control group, 10 cases in the SD group and 9 cases in the PD group. The effective rate was 70.0% There was no significant difference between the two groups (χ2 = 0.431, P> 0.05). Conclusion: The combination of irinotecan with leucovorin and fluorouracil in the treatment of advanced gastric cancer patients has obvious clinical effect and can be used as first-line chemotherapy for advanced gastric cancer.